Wednesday, 26 August 2026European Markets

FONCIERE EURIS Stock Went Down By Over 30% In The Last 21 Sessions

Loading stream...

(vianews) - shares of fonciere euris (cac 40: eurs.pa) slid by a staggering 30.4% in 21 sessions from €2.5 to €1.74 at 11:53 est on wednesday, after three successive sessions in a row of losses. cac 40 is falling 1.61% to €7,259.73, after two sequential sessions in a row of losses.

about fonciere euris

foncière euris sa distributes food and specialized products in france and internationally. the company also owns real estate assets, including shopping centers; and manages commercial real estate properties and private equity portfolio. the company was incorporated in 1970 and is based in paris, france. foncière euris sa operates as a subsidiary of finatis société anonyme.

earnings per share

as for profitability, fonciere euris has a trailing twelve months eps of €-12.12.

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, fonciere euris's stock is considered to be overbought (>=80).

volatility

fonciere euris's last week, last month's, and last quarter's current intraday variation average was a negative 3.67%, a negative 3.41%, and a positive 6.37%.

fonciere euris's highest amplitude of average volatility was 6.30% (last week), 6.37% (last month), and 6.37% (last quarter).

volume

today's last reported volume for fonciere euris is 1 which is 91.52% below its average volume of 425.

more news about fonciere euris (eurs.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Leadership Exodus Rattles Investor Confidence Amid Capex Boom
High-profile departures at top AI labs — Brad Lightcap's exit from OpenAI and an unnamed researcher's departure from Alphabet/Google that triggered a share-price drop — are surfacing talent retention as a market risk factor even as hyperscalers pour record capital into AI infrastructure. The reaction shows investors treating key-person risk at frontier AI labs as material to valuation, a new fragility layered onto an otherwise bullish AI-driven capex cycle.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Broadcom Inc.
Both facts report EPS for Broadcom Inc. for the same fiscal period (Q1 2026) observed on the same date (2026-02-01). However, they report conflicting values: 1.5 USD per share vs 2.05 USD per share. This is a 37% difference for the identical metric and time period, not a value change over time.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,978
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,978 facts checked against source5,251 source documents archived
Query this data → isubstrate.com